Your browser doesn't support javascript.
Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern.
Griffin, Amanda J; O'Donnell, Kyle L; Shifflett, Kyle; Lavik, John-Paul; Russell, Patrick M; Zimmerman, Michelle K; Relich, Ryan F; Marzi, Andrea.
  • Griffin AJ; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA.
  • O'Donnell KL; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA.
  • Shifflett K; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA.
  • Lavik JP; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Russell PM; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Zimmerman MK; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Relich RF; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
  • Marzi A; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, 59840, USA. marzia@niaid.nih.gov.
Sci Rep ; 12(1): 3954, 2022 03 10.
Article in English | MEDLINE | ID: covidwho-1740473
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) results in a variety of clinical symptoms ranging from no or mild to severe disease. Currently, there are multiple postulated mechanisms that may push a moderate to severe disease into a critical state. Human serum contains abundant evidence of the immune status following infection. Cytokines, chemokines, and antibodies can be assayed to determine the extent to which a patient responded to a pathogen. We examined serum and plasma from a cohort of patients infected with SARS-CoV-2 early in the pandemic and compared them to negative-control sera. Cytokine and chemokine concentrations varied depending on the severity of infection, and antibody responses were significantly increased in severe cases compared to mild to moderate infections. Neutralization data revealed that patients with high titers against an early 2020 SARS-CoV-2 isolate had detectable but limited neutralizing antibodies against the emerging SARS-CoV-2 Alpha, Beta and Delta variants. This study highlights the potential of re-infection for recovered COVID-19 patients.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-07960-4

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Broadly Neutralizing Antibodies / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-07960-4